Pharmathene Inc (PIP) 1.42 $PIP
PharmAthene (PIP) Crumbles: Stock Falls by 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:51AM CDT
PharmAthene saw a big move last session, as the company’s shares fell by over 7% on the day
PharmAthene Updates Status Of SparVax® Anthrax Vaccine Contract
PR Newswire - Mon Apr 07, 8:00AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has received notice from the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), advising the Company of its decision to de-scope the current SparVax® anthrax vaccine contract through a partial termination for convenience. BARDA will provide additional guidance to PharmAthene on the contractual changes, following which PharmAthene will evaluate its options with respect to its SparVax® program.
PharmAthene Presents SparVax® Anthrax Vaccine Data at the New Technologies New Vaccines 2014 Conference
PR Newswire - Tue Apr 01, 1:42PM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that data from the Company's SparVax® next-generation anthrax vaccine program were recently presented at the 8th Annual New Technologies, New Vaccines conference. In a presentation entitled, "Factors that Affect Potency and Stability for a Recombinant Protective Antigen Vaccine," Dr. Bradford Powell, Director, Analytical Sciences at PharmAthene, presented results demonstrating the Company's achievements in developing key analytical assays which are being employed to monitor the stability and potency of SparVax®.
PharmAthene Reports Year-End 2013 Financial And Operational Results
PR Newswire - Tue Mar 11, 3:00PM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the year ended December 31, 2013.
PharmAthene to Host Year-End 2013 Conference Call and Webcast on Tuesday, March 11, 2014
PR Newswire - Mon Mar 10, 11:20AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial and operational results for the year ended 2013 will be released on Tuesday, March 11, 2014.
FTC Grants Early Termination of Hart-Scott-Rodino Act Waiting Period for Merger Transaction between Kroger and Harris Teeter
PR Newswire - Fri Jan 17, 4:34PM CST
The Kroger Co. (NYSE: KR) ("Kroger"
and Harris Teeter Supermarkets, Inc. (NYSE: HTSI) ("Harris Teeter" announced that the Federal Trade Commission today granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR" with respect to the pending merger transaction between the two companies.
Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment
PR Newswire - Tue Jan 14, 11:30AM CST
Dynamic Healthcare Services, Inc. ("DHS", a portfolio company of GMH Ventures LLC ("GMH", announced today that it acquired Progressive Home Medical Equipment, Inc. ("Progressive" of Clarion, PA on January 7, 2014. The terms of the acquisition were not disclosed.
Consider Buy Rated Stocks Under Five Bucks as Stocking Stuffers
at The Street - Mon Dec 23, 9:28AM CST
Advanced Micro and Alaska Communications lead nine stocks trading under $5 as speculative stocking stuffers for possible positive returns in 2014.
PharmAthene Inc's SparVax rPA anthrax vaccine programme put on clinical hold by US FDA
M2 - Tue Dec 17, 5:30AM CST
PharmAthene Inc (NYSE MKT
IP) said on Monday that the U.S. Food and Drug Administration (FDA) has placed its SparVax rPA anthrax vaccine programme on clinical hold.
PharmAthene Receives FDA Notification On SparVax®
PR Newswire - Mon Dec 16, 7:00AM CST
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today it has received notification from the U.S. Food and Drug Administration (FDA) that its SparVax® rPA anthrax vaccine program has been placed on clinical hold. The Agency indicated that the Company will receive a letter providing details of the basis for the clinical hold within thirty days. The Phase II clinical study, which was expected to begin by the end of this year, has not enrolled any subjects to date and accordingly, there have been no adverse events reported.
PharmAthene Announces Termination Of Merger Agreement With Theraclone Sciences
PR Newswire - Mon Dec 02, 8:00AM CST
PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has terminated its definitive merger agreement with Theraclone Sciences, Inc. with consent from Theraclone. The agreement provided for the merger of a wholly-owned subsidiary of PharmAthene into Theraclone in an all-stock, merger-of-equals transaction. Accordingly, PharmAthene has cancelled the Special Meeting of Stockholders scheduled for December 3, 2013 and will pay Theraclone a $1 million termination fee.
Update - Prescott Group Urges All PharmAthene Shareholders to Vote Against Proposed Theraclone Merger
Business Wire - Fri Nov 29, 6:00AM CST
Prescott Group Capital Management, a greater than 10% shareholder of PharmAthene, Inc. (NYSE MKT: PIP), who has previously urged shareholders to vote against the Theraclone merger based largely on the lack of proper disclosures, now questions the quality of due diligence performed by PharmAthene's Board of Directors after Theraclone announced on November 27, 2013 that:
Prescott Group Urges All PharmAthene Shareholders to Vote AGAINST Proposed Theraclone Merger
Business Wire - Wed Nov 27, 6:00AM CST
Prescott Group Capital Management, a greater than 10% shareholder of PharmAthene, Inc. (NYSE MKT: PIP), urges all stockholders to vote AGAINST the issuance of shares needed to complete the proposed merger with Theraclone Sciences, Inc. and AGAINST giving PharmAthene the right to adjourn the upcoming special meeting. Prescott notes that Institutional Shareholder Services Inc. (ISS), a leading provider of corporate governance solutions, also recommends that PharmAthene stockholders vote AGAINST both of these key proposals. Additionally, Prescott urges shareholders to vote AGAINST all five proposals being submitted to a vote of PharmAthene stockholders at the scheduled December 3rd special meeting.
New PharmAthene SparVax® Anthrax Vaccine Data Published In Clinical and Vaccine Immunology
PR Newswire - Mon Nov 11, 8:47AM CST
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that new data from the Company's next-generation SparVax® recombinant protective antigen (rPA) anthrax vaccine program were published in the November issue of the American Society for Microbiology peer-reviewed journal Clinical and Vaccine Immunology.
PharmAthene Reports Third Quarter 2013 Financial And Operational Results
PR Newswire - Thu Nov 07, 3:30PM CST
Recent Highlights
5 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Oct 23, 6:00AM CDT
New Non-Clinical Data Confirm SparVax® Anthrax Vaccine Can Provide Protection Against Lethal Anthrax Challenge
PR Newswire - Fri Sep 13, 7:34AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that new non-clinical animal data from the Company's SparVax® next-generation anthrax vaccine program were presented at the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Co. The data presented showed that immunization with SparVax® provides dose-dependent protection against lethal anthrax infection.
Investors look to Lighten Up on Shares of PharmAthene, Shares Down 6.2% (PIP)
Comtex SmarTrend(R) - Tue Sep 10, 10:15AM CDT
PharmAthene (AMEXIP) is one of today's worst performing low-priced stocks, down 6.2% to $1.97 on 1.0x average daily volume. Thus far today, PharmAthene has traded 369,000 shares, vs. average volume of 351,000 shares per day. The stock has underperformed the Dow (-6.2% to the Dow's 0.7%) and underperformed the S&P 500 (-6.2% to the S&P's 0.7%) during today's trading.
PharmAthene Inc files registration statement in connection with its merger with Theraclone Sciences Inc
M2 - Tue Sep 10, 7:25AM CDT
PharmAthene Inc (NYSE MKTIP) said on Monday that it has filed a registration statement on Form S-4 with the Securities and Exchange Commission (SEC) in connection with its merger with Theraclone Sciences Inc.
PharmAthene Files Registration Statement On Form S-4 With The Securities and Exchange Commission
PR Newswire - Mon Sep 09, 7:20AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has filed a registration statement on Form S-4 with the Securities and Exchange Commission (SEC) containing a preliminary proxy statement / prospectus / consent solicitation in connection with the previously announced merger between PharmAthene, Inc., and Theraclone Sciences, Inc., a privately-held monoclonal antibody (mAb) discovery and development company.
PharmAthene (PIP) Crumbles: Stock Falls by 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:51AM CDT
PharmAthene saw a big move last session, as the company’s shares fell by over 7% on the day
PharmAthene Updates Status Of SparVax® Anthrax Vaccine Contract
PR Newswire - Mon Apr 07, 8:00AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has received notice from the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), advising the Company of its decision to de-scope the current SparVax® anthrax vaccine contract through a partial termination for convenience. BARDA will provide additional guidance to PharmAthene on the contractual changes, following which PharmAthene will evaluate its options with respect to its SparVax® program.
PharmAthene Presents SparVax® Anthrax Vaccine Data at the New Technologies New Vaccines 2014 Conference
PR Newswire - Tue Apr 01, 1:42PM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that data from the Company's SparVax® next-generation anthrax vaccine program were recently presented at the 8th Annual New Technologies, New Vaccines conference. In a presentation entitled, "Factors that Affect Potency and Stability for a Recombinant Protective Antigen Vaccine," Dr. Bradford Powell, Director, Analytical Sciences at PharmAthene, presented results demonstrating the Company's achievements in developing key analytical assays which are being employed to monitor the stability and potency of SparVax®.
PharmAthene Reports Year-End 2013 Financial And Operational Results
PR Newswire - Tue Mar 11, 3:00PM CDT
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the year ended December 31, 2013.
PharmAthene to Host Year-End 2013 Conference Call and Webcast on Tuesday, March 11, 2014
PR Newswire - Mon Mar 10, 11:20AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial and operational results for the year ended 2013 will be released on Tuesday, March 11, 2014.
FTC Grants Early Termination of Hart-Scott-Rodino Act Waiting Period for Merger Transaction between Kroger and Harris Teeter
PR Newswire - Fri Jan 17, 4:34PM CST
The Kroger Co. (NYSE: KR) ("Kroger"
and Harris Teeter Supermarkets, Inc. (NYSE: HTSI) ("Harris Teeter" announced that the Federal Trade Commission today granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR" with respect to the pending merger transaction between the two companies. Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment
PR Newswire - Tue Jan 14, 11:30AM CST
Dynamic Healthcare Services, Inc. ("DHS"
, a portfolio company of GMH Ventures LLC ("GMH", announced today that it acquired Progressive Home Medical Equipment, Inc. ("Progressive" of Clarion, PA on January 7, 2014. The terms of the acquisition were not disclosed. Consider Buy Rated Stocks Under Five Bucks as Stocking Stuffers
at The Street - Mon Dec 23, 9:28AM CST
Advanced Micro and Alaska Communications lead nine stocks trading under $5 as speculative stocking stuffers for possible positive returns in 2014.
PharmAthene Inc's SparVax rPA anthrax vaccine programme put on clinical hold by US FDA
M2 - Tue Dec 17, 5:30AM CST
PharmAthene Inc (NYSE MKT
IP) said on Monday that the U.S. Food and Drug Administration (FDA) has placed its SparVax rPA anthrax vaccine programme on clinical hold. PharmAthene Receives FDA Notification On SparVax®
PR Newswire - Mon Dec 16, 7:00AM CST
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today it has received notification from the U.S. Food and Drug Administration (FDA) that its SparVax® rPA anthrax vaccine program has been placed on clinical hold. The Agency indicated that the Company will receive a letter providing details of the basis for the clinical hold within thirty days. The Phase II clinical study, which was expected to begin by the end of this year, has not enrolled any subjects to date and accordingly, there have been no adverse events reported.
PharmAthene Announces Termination Of Merger Agreement With Theraclone Sciences
PR Newswire - Mon Dec 02, 8:00AM CST
PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has terminated its definitive merger agreement with Theraclone Sciences, Inc. with consent from Theraclone. The agreement provided for the merger of a wholly-owned subsidiary of PharmAthene into Theraclone in an all-stock, merger-of-equals transaction. Accordingly, PharmAthene has cancelled the Special Meeting of Stockholders scheduled for December 3, 2013 and will pay Theraclone a $1 million termination fee.
Update - Prescott Group Urges All PharmAthene Shareholders to Vote Against Proposed Theraclone Merger
Business Wire - Fri Nov 29, 6:00AM CST
Prescott Group Capital Management, a greater than 10% shareholder of PharmAthene, Inc. (NYSE MKT: PIP), who has previously urged shareholders to vote against the Theraclone merger based largely on the lack of proper disclosures, now questions the quality of due diligence performed by PharmAthene's Board of Directors after Theraclone announced on November 27, 2013 that:
Prescott Group Urges All PharmAthene Shareholders to Vote AGAINST Proposed Theraclone Merger
Business Wire - Wed Nov 27, 6:00AM CST
Prescott Group Capital Management, a greater than 10% shareholder of PharmAthene, Inc. (NYSE MKT: PIP), urges all stockholders to vote AGAINST the issuance of shares needed to complete the proposed merger with Theraclone Sciences, Inc. and AGAINST giving PharmAthene the right to adjourn the upcoming special meeting. Prescott notes that Institutional Shareholder Services Inc. (ISS), a leading provider of corporate governance solutions, also recommends that PharmAthene stockholders vote AGAINST both of these key proposals. Additionally, Prescott urges shareholders to vote AGAINST all five proposals being submitted to a vote of PharmAthene stockholders at the scheduled December 3rd special meeting.
New PharmAthene SparVax® Anthrax Vaccine Data Published In Clinical and Vaccine Immunology
PR Newswire - Mon Nov 11, 8:47AM CST
PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that new data from the Company's next-generation SparVax® recombinant protective antigen (rPA) anthrax vaccine program were published in the November issue of the American Society for Microbiology peer-reviewed journal Clinical and Vaccine Immunology.
PharmAthene Reports Third Quarter 2013 Financial And Operational Results
PR Newswire - Thu Nov 07, 3:30PM CST
Recent Highlights
5 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Oct 23, 6:00AM CDT
New Non-Clinical Data Confirm SparVax® Anthrax Vaccine Can Provide Protection Against Lethal Anthrax Challenge
PR Newswire - Fri Sep 13, 7:34AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that new non-clinical animal data from the Company's SparVax® next-generation anthrax vaccine program were presented at the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Co. The data presented showed that immunization with SparVax® provides dose-dependent protection against lethal anthrax infection.
Investors look to Lighten Up on Shares of PharmAthene, Shares Down 6.2% (PIP)
Comtex SmarTrend(R) - Tue Sep 10, 10:15AM CDT
PharmAthene (AMEX
IP) is one of today's worst performing low-priced stocks, down 6.2% to $1.97 on 1.0x average daily volume. Thus far today, PharmAthene has traded 369,000 shares, vs. average volume of 351,000 shares per day. The stock has underperformed the Dow (-6.2% to the Dow's 0.7%) and underperformed the S&P 500 (-6.2% to the S&P's 0.7%) during today's trading. PharmAthene Inc files registration statement in connection with its merger with Theraclone Sciences Inc
M2 - Tue Sep 10, 7:25AM CDT
PharmAthene Inc (NYSE MKT
IP) said on Monday that it has filed a registration statement on Form S-4 with the Securities and Exchange Commission (SEC) in connection with its merger with Theraclone Sciences Inc. PharmAthene Files Registration Statement On Form S-4 With The Securities and Exchange Commission
PR Newswire - Mon Sep 09, 7:20AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has filed a registration statement on Form S-4 with the Securities and Exchange Commission (SEC) containing a preliminary proxy statement / prospectus / consent solicitation in connection with the previously announced merger between PharmAthene, Inc., and Theraclone Sciences, Inc., a privately-held monoclonal antibody (mAb) discovery and development company.
